Fat accumulation in *Caenorhabditis elegans* triggered by the electrophilic lipid peroxidation product 4-Hydroxynonenal (4-HNE)

Sharda P. Singh, ¹ Maciej Niemczyk, ¹ Ludwika Zimniak, ¹ Piotr Zimniak ¹,²

¹Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
²Central Arkansas Veterans Healthcare System, Little Rock, AR 72205, USA

**Running title:** 4-HNE triggers fat accumulation in *C. elegans*

**Keywords:** Lipid peroxidation; 4-hydroxynonenal; malonyl-CoA; acetyl-CoA carboxylase; citrate; obesity

**Correspondence:** Piotr Zimniak, PhD, Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, 4301 W. Markham St. Little Rock, AR 72205, USA

**Received:** 11/17/08; accepted: 12/12/08; published on line: 12/18/08

**E-mail:** zimniakpiotr@uams.edu

**Copyright:** © 2009 Singh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Abstract:** Deposition and mobilization of fat in an organism are tightly controlled by multiple levels of endocrine and neuroendocrine regulation. Because these hormonal mechanisms ultimately act by affecting biochemical reactions of fat synthesis or utilization, obesity could be also modulated by altering directly the underlying lipid biochemistry. We have previously shown that genetically modified mice with an elevated level of the lipid peroxidation product 4-HNE become obese. We now demonstrate that the process is phylogenetically conserved and thus likely to be universal. In the nematode *C. elegans*, disruption of either conjugation or oxidation of 4-HNE leads to fat accumulation, whereas augmentation of 4-HNE conjugation results in a lean phenotype. Moreover, direct treatment of *C. elegans* with synthetic 4-HNE causes increased lipid storage, directly demonstrating a causative role of 4-HNE. The postulated mechanism, which involves modulation of acetyl-CoA carboxylase activity, could contribute to the triggering and maintenance of the obese phenotype on a purely metabolic level.

**INTRODUCTION**

4-Hydroxynonenal (4-HNE) is the product of peroxidation of n-6 polyunsaturated fatty acids [1, 2]. 4-HNE is strongly electrophilic and thus bioactive because of its potential to modify biological macromolecules, particularly proteins, via the formation of covalent adducts [3, 4]. These chemical properties of 4-HNE render the compound toxic at high concentrations [3]. However, at moderate (physiological) levels [5], 4-HNE acts as a messenger molecule that signals the presence of a pro-oxidant state and elicits a variety of appropriate biological responses [reviewed in refs. 4, 6-9]. In this context, lipid peroxidation acts as a sensor that registers the presence of oxidants and translates it into the generation of electrophiles such as 4-HNE. Compared with oxidants such as most types of ROS (reactive oxygen species), 4-HNE is chemically better suited for the role of a signaling molecule because of its longer half-life and thus greater range of diffusion, and a higher selectivity for reaction with specific targets.

Multiple physiological and pathophysiological situations can result in oxidative stress. Among them is excessive fat accumulation that leads to mild but chronic inflammation characterized by focal necrosis and recruitment of macrophages to the adipose tissue; inflammation is both local and systemic [10-12]. The oxidative stress that accompanies inflammation would be expected to trigger lipid peroxidation and 4-HNE production. Indeed, higher levels of 4-HNE have been...
found in obese than in non-obese humans and mice [13, 14].

Several biologically fundamental target processes responsive to 4-HNE signaling have been identified, including modulation of apoptosis, activation of stress response pathways, cell proliferation and differentiation, mitochondrial coupling, and others [reviewed in refs. 9, 15-18]. Results presented in this paper, together with our previous data [19], define a new target of 4-HNE signaling: adipogenesis. This would place 4-HNE not only downstream [14] but also upstream of fat accumulation, resulting in a positive feedback loop. In this paper, we present evidence for a biochemical mechanism by which 4-HNE could trigger increased lipid storage, and discuss possible adaptive and maladaptive roles of the self-reinforcing loop that involves triglycerides and 4-HNE, in particular, in the context of aging.

RESULTS

Expression of the gates-10 gene product, which is capable of conjugating 4-HNE, is inversely related to the level of whole-body 4-HNE-protein adducts

As we have previously shown [20, 21], the capacity of C. elegans to conjugate 4-HNE with glutathione was reduced by RNAi-mediated knockdown of CeGSTP2-2, the product of the gates-10 gene. The loss of 4-HNE-conjugating activity was only partial because of the existence of multiple GSTs capable of conjugating 4-HNE [20]. Nevertheless, silencing of gates-10 resulted in a greater than 50% increase of the level of whole-body 4-HNE-protein adducts (Figure 1). Conversely, overexpression of gates-10 results in an enhanced capacity to conjugate 4-HNE and in a decrease in the content of 4-HNE-protein adducts [22]. Because the biological effects of 4-HNE are thought to be mediated mostly by formation of covalent adducts with proteins, a process that frequently alters protein function [reviewed in refs. 4-6, 9], the observed changes in adduct amounts could be functionally significant.

Fat accumulation in C. elegans is inversely proportional to the expression level of gates-10

Worms subjected to RNAi against gates-10 accumulate significant amounts of fat (Figures 2A and 2B). The use of two independent lipid stains, Nile red [23, 24] and Sudan black [25], minimizes the likelihood of artifacts.

In contrast to animals subjected to RNAi, several C. elegans lines overexpressing the gates-10 gene product [22] had a lean phenotype (Figure 2C). This lean phenotype was confirmed using a second, independently derived control line carrying an insert-free vector (data not shown), thus establishing that the low fat content of gates-10-overexpressing worms was not due to an aberrant control line. The data demonstrate an inverse proportionality between gates-10-linked 4-HNE-conjugating activity and fat accumulation in C. elegans.

Disruption of oxidative metabolism of 4-HNE leads to a fat accumulation phenotype resembling that seen in 4-HNE conjugation-defective C. elegans

In addition to glutathione conjugation, 4-HNE can undergo reductive or oxidative metabolism [reviewed in refs. 5, 6]. In mammalian cells, several aldehyde dehydrogenases that catalyze the oxidation of the carbonyl group of 4-HNE are physiologically important [2, 26, 27]. Of the twelve aldehyde dehydrogenase (alh) genes of C. elegans (WormBase release WS194), we investigated alh-1 which has a high, and alh-10 which
has a moderate contribution to whole-body NAD⁺-dependent 4-HNE oxidation (Figure 3A). Silencing of the alh-1 gene led to a statistically significant increase in fat accumulation, as measured either by Nile red (Figure 3B) or by Sudan black (Figure 3C) staining. In contrast, RNAi against alh-10 had no effect on the level of stored lipids (Figure 3B and C). These results show that the inverse relationship between the accumulation of fat and the organism’s capacity to metabolize 4-HNE is not limited to glutathione conjugation of 4-HNE by the gst-10 gene product, but that it extends to another type of 4-HNE metabolism catalyzed by an unrelated enzyme.

Direct exposure of *C. elegans* to synthetic 4-HNE leads to an increase of 4-HNE-protein adducts and causes the fat accumulation phenotype

Treatment of *C. elegans* in liquid culture with chemically synthesized 4-HNE caused an increase in the level of 4-HNE-protein adducts (Figure 4). This increase was greater than that seen in worms subjected to RNAi against gst-10 (Figure 1), possibly because gst-10 expression is restricted to relatively few cells of *C. elegans* [22]. Given the limitations on long-range diffusion of 4-HNE [28], the effects on 4-HNE that result from gst-10 disruption may also be local, and would appear as moderate when averaged over the entire organism. In contrast, most or all tissues are likely to be affected in worms exposed to 4-HNE-containing medium. In addition to the tissue distribution of 4-HNE, the relatively high concentration (1 mM) of the compound in the growth medium could have also contributed to the pronounced increase in adducts. However, it is important to note that the biologically active concentration of 4-HNE in tissues of *C. elegans* is approximately three orders of magnitude lower than the concentration of externally added 4-HNE [20]. Thus, the effective 4-HNE concentration was likely on the order of 1 μM, well within a physiologically achievable range [low micromolar; ref. 5].

Exposure of *C. elegans* to synthetic 4-HNE led to storage of excess lipids that increased with increasing medium concentration of 4-HNE, as shown by either Nile red or Sudan black staining (Figure 5A and B, respectively). No significant fluorescence was visible in the absence of Nile red (Figure 5A, upper row of images), demonstrating that the observed signal is not caused by increased autofluorescence in response to the treatment with 4-HNE. This is important because 4-HNE has been implicated in the process of lipofuscin formation [29]. Similarly, there was no signal in brightfield images of worms treated with 4-HNE but not stained (Figure 5B, upper row), whereas identically treated animals that were stained with Sudan black yielded a strong signal under the same exposure conditions (Figure 5B, lower row of images). Quantitation of multiple images shows that the amount of accumulated fat was linearly proportional to the medium concentration of 4-HNE in the range of 0.25 – 2 mM (Figure 5C).
Fat accumulation triggered by 4-HNE is accompanied by metabolic changes consistent with increased de novo synthesis and/or decreased β-oxidation of fatty acids

Malonyl-CoA is a metabolite of key importance in lipid homeostasis (see Discussion). Malonyl-CoA was measured in *C. elegans* in which the level of 4-HNE was increased by either of two methods: direct treatment with 4-HNE, or RNAi against *gst-10* which leads to an impairment of 4-HNE removal. In both situations, the concentration of malonyl-CoA was elevated (Figure 6A and B). Worms treated in the same way were also assayed for citrate, a precursor and activator of malonyl-CoA synthesis (see Discussion). In analogy to malonyl-CoA, the concentration of citrate was increased as a consequence of diminished metabolic elimination of 4-HNE or in response to direct supplementation of worms with 4-HNE (Figure 7).

**DISCUSSION**

Experimental manipulation of enzymes that catalyze elimination of 4-HNE from tissues modulates the steady-state level of 4-HNE and affects the amount of stored fat in *C. elegans*. Specifically, inhibition of either conjugation or oxidation of 4-HNE leads to increased fat accumulation, whereas overexpression of a 4-HNE-conjugating enzyme results in a lean phenotype (Figure 2 and Figure 3). These observations are consistent with the obese phenotype we have previously reported for *mGsta4* null mice which have an impaired ability to conjugate 4-HNE [19], indicating that the link between abundance of 4-HNE and fat storage is conserved between evolutionarily distant species.

We propose that 4-HNE, rather than another substrate or function of the enzymes that are being experimentally manipulated, is a causative factor in the enhanced storage of lipid. We favor this model for the following reasons:

(i) Except for 4-HNE, there is no known common substrate of the two rather dissimilar *C. elegans* enzymes used in the present work, i.e., the products of *gst-10* and *alh-1* genes. Moreover, 4-HNE is the only known common substrate of the above-mentioned two enzymes and the murine mGSTA4-4 [30].

(ii) Fat deposition was reported for yeast directly treated with 4-HNE [31], an experimental design that points to 4-HNE as the causative agent.

(iii) *mGsta4* null mice in the 129/sv genetic background have an elevated tissue levels of 4-HNE and are obese, while *mGsta4* null mice in C57BL genetic background have near-normal levels of 4-HNE and are not obese [19]. The proportionality of 4-HNE and fat deposition in otherwise closely related systems suggests a causal role of 4-HNE in lipid accumulation in the murine model.

(iv) Overexpression of murine aldose reductase Akr1b7 [an enzyme catalyzing reductive metabolism of 4-HNE, ref. 32] inhibits adipogenesis, and disruption of the same enzyme accelerates adipogenesis [33]. Concordant results obtained with mGSTA4-4 and Akr1b7 indicate that a common substrate, such as 4-HNE, is responsible for the phenotype.

While alternative explanations could be invoked for each of the findings listed above, a strong case for a causal involvement of 4-HNE can be made if the arguments are considered in aggregate. It is unlikely that several enzymes that act on distinct functional groups of 4-HNE would all share a hypothetical additional substrate. The reactions these enzymes catalyze include Michael addition of a nucleophile to a polarized double bond (GSTs), NAD⁺-dependent oxidation of an aldehyde to a carboxylic acid (aldehyde dehydrogenase), and NAD(P)H-dependent reduction of

---

Figure 4. Increased level of 4-HNE-protein adducts in *C. elegans* treated with 4-HNE. Synchronized L4 worms were kept in liquid culture for 3 days in medium containing 1 mM 4-HNE. The medium was replaced every 12 hr with fresh medium containing 4-HNE. The level of 4-HNE-protein adducts was determined in 5-day-old worms by competitive ELISA [93]. The values shown are means ± S.D. of 4 biological replicates (independently grown batches of worms) per group.
an aldehyde to an alcohol (aldose reductase). To be able to undergo all three reactions, a substrate must contain the requisite target functional groups; this requirement restricts the set of possible substrates to $\alpha, \beta$-unsaturated carbonyl compounds such as 4-HNE. Moreover, experimental interventions that lower the expression of 4-HNE-conjugating GSTs in *C. elegans* ($gst-10$) and in mice (mGSTA4-4) resulted in a similar phenotype, i.e., increased fat storage. The two enzymes are not orthologs, and their ability to conjugate 4-HNE probably evolved independently [22, 34]. It is unlikely that both enzymes acquired by chance another shared activity or function that is unrelated to conjugation of 4-HNE, indicating that the parallel effects of disrupting mGSTA4-4 and $gst-10$ are indeed mediated by 4-HNE.

As outlined above, experimental modulation of 4-HNE-metabolizing enzymes indicates that 4-HNE can trigger fat accumulation. However, even though highly persuasive, the evidence is indirect. The existence of an alternative substrate of the three 4-HNE-metabolizing enzymes is unlikely but cannot be ruled out with certainty. In addition, decreasing the expression of the three enzymes could lead to lipid accumulation via three independent mechanisms, none of them involving 4-HNE – a hypothesis that is implausible but not impossible. Therefore, we wished to test a possible causative role of 4-HNE without relying on enzymes.

Figure 5. Effects of direct treatment with 4-HNE on lipid accumulation in *C. elegans*. Synchronized L4 worms were kept in liquid culture for 3 days in medium containing the indicated concentration of 4-HNE. The medium was replaced every 12 hr with fresh medium containing 4-HNE but not stained (upper row of images), and animals exposed to 4-HNE and stained with Nile red (lower row of images). Panel B: brightfield images of worms treated with the indicated concentration of 4-HNE and directly photographed (upper row of images), or photographed after staining with Sudan black (lower row of images). Panel C: for each 4-HNE concentration, lipid content was measured in three independently treated worm populations by quantitation of Nile red fluorescence (upper plot) or Sudan black staining (lower plot).
For this purpose, we took advantage of the unique experimental opportunities afforded by *C. elegans*, a multicellular animal that can be handled by methods developed for microorganisms or cultured cells [35]. This includes the option to grow *C. elegans* in liquid medium that can be supplemented with compounds to be tested. Exposure of *C. elegans* to synthetic 4-HNE led to dose-dependent lipid deposition (Figure 5) similar to that triggered by silencing of either *gst-10* or *alh-1*. While this finding does not formally rule out the possibility that hypothetical alternative substrates of *gst-10* and *alh-1* are also involved, it proves that 4-HNE is sufficient to elicit the fat accumulation phenotype.

![Figure 6. Effect of increased 4-HNE levels on malonyl-CoA concentration.](image)

*Figure 6. Effect of increased 4-HNE levels on malonyl-CoA concentration.* *C. elegans* were either treated with 1 mM 4-HNE according to the protocol described in the legend of Figure 5 (panel A) or subjected to RNAi to *gst-10* (panel B). The results were normalized to the respective control and are shown as mean ± S.D. of 3 independently grown worm populations. In panel A, the control (*C. elegans* Bristol-N2 in liquid culture in the presence of *E. coli* OP50 but without 4-HNE) contained 16.5 ± 1.2 ng malonyl-CoA/mg dry weight; in panel B, the level of malonyl-CoA in the control (*C. elegans* Bristol-N2 grown on plates seeded with *E. coli* HT115(DE3) transformed with insert-free L4440 feeding vector) was 12.2 ± 0.8 ng/mg dry weight.

The increase in stored fat was similar for worms directly exposed to 4-HNE (Figure 5) and for those with silenced 4-HNE-metabolizing enzymes (Figure 2 and Figure 3), even though the former treatment was markedly more effective in raising the level of 4-HNE-protein adducts (Figure 4 versus Figure 1). These findings could indicate that silencing *gst-10* or *alh-1* raises the concentration of 4-HNE in selected tissues, including those involved in regulating fat storage. In contrast, exposure of animals to external 4-HNE is likely to affect the entire body. Either treatment would reach the critical target tissues and trigger fat accretion, but exposure to 4-HNE in the medium would generate more total 4-HNE adducts. Further work is needed to identify the cells or tissues that are required for increased fat storage in response to 4-HNE, although head neurons are a possibility. Head neurons express the *gst-10* [22] as well as the *alh-1* gene products (WormBase release WS194).

What is the molecular mechanism by which 4-HNE increases the level of stored fat? A clue is offered by our finding that the concentration of malonyl-CoA was increased in *C. elegans* with disrupted enzymatic removal of 4-HNE, as well as in animals directly exposed to 4-HNE (Figure 6). Malonyl-CoA has a dual metabolic function: it is the substrate for fatty acid synthesis, and it prevents fatty acid β-oxidation [reviewed in ref. 36]. Therefore, elevated malonyl-CoA levels lead to an accumulation of fatty acids and, consequently, of triglycerides. In fact, experimental lowering of malonyl-CoA levels results in a lean phenotype in mammals [37-39] as well as in *C. elegans* [40]. Conversely, liver-specific disruption of AMPK, expected to increase malonyl-CoA levels, results in elevated hepatic lipogenesis [41, 42]. These data indicate that the higher level of malonyl-CoA that we observed in worms with increased 4-HNE could account for the concomitant fat accumulation.

Malonyl-CoA is formed from acetyl-CoA by the enzyme acetyl-CoA carboxylase (ACC). Although the steady-state tissue concentration of malonyl-CoA depends on the rate of its synthesis by ACC as well as its removal rate by fatty acid synthase or by malonyl-CoA decarboxylase, the activity of ACC is considered to be the major physiological determinant of malonyl-CoA levels at least in some tissues [43]. Therefore, the regulation of ACC activity is of central importance for fat homeostasis. Not surprisingly, ACC has been proposed as a target for pharmacological intervention [39, 44].

Regulation of ACC is mostly post-translational. In mammals, a major regulatory mode is phosphorylation, particularly by AMPK [45, 46]. Although *C. elegans* ACC lacks the canonical target sequence for AMPK phosphorylation [47], worm ACC is probably still regulated by AMPK, perhaps using an alternative phosphorylation site, because AMPK is required for metabolic modulation of fat stores [48]. Further work will be needed to elucidate the details of ACC phosphorylation in *C. elegans*. 

![Figure 4.](image)
In addition to phosphorylation, ACC is acutely regulated by allosteric effectors including citrate [reviewed in refs. 47, 49]. In the well-fed state, excess citrate is withdrawn from the TCA cycle and transported out of mitochondria. In the cytosol, citrate has a dual function in fat synthesis: (i) it allosterically activates ACC, and (ii) it is converted by citrate lyase to acetyl-CoA, the substrate of ACC (Figure 8). The resulting higher flux through ACC increases the supply of malonyl-CoA.

A partial inhibition of the tricarboxylic acid cycle enzyme aconitase lead to increased steady-state levels of citrate [50]. This is relevant to the present work because aconitase is susceptible to inhibition by 4-HNE. It has been reported that adducts of 4-HNE with aconitase form when isolated mitochondria are exposed to 4-HNE [ref. 51 and references therein], and that treatment of cultured cells with 4-HNE leads to a decrease in aconitase activity [52]. We found that mGsta4 knockout mice have lower aconitase activity and higher citrate levels than wild-type animals [19]. We now demonstrate that increasing the levels of 4-HNE, either by direct treatment with the compound or by disruption of the metabolic disposal of 4-HNE, results in an elevated citrate concentration in C. elegans [50]. Thus, our results support a model in which 4-HNE partially inhibits aconitase, causing an increase in the steady-state concentration of citrate. The latter metabolite augments the flux through ACC by providing both the substrate and the allosteric activator of the enzyme. This leads to more malonyl-CoA production, and thus to more fatty acid synthesis and less fatty acid β-oxidation. The accumulating fatty acids are converted to storage fat. The model is schematically depicted in Figure 8.

We propose that the chain of events leading from 4-HNE to increased fat storage operates not only when 4-HNE levels are experimentally perturbed, but that it is part of normal physiology. In the wild, access to food is typically intermittent. It is therefore highly adaptive to maximize stores of metabolic fuel when food is available. Such stores increase the probability of surviving “lean” periods. Feeding triggers the synthesis and deposition of fat. At least in mammals, increased fat storage correlates with a more pronounced pro-inflammatory and pro-oxidative state [53, 54]. Oxidative stress is expected to facilitate lipid peroxidation and raise 4-HNE levels. In fact, it has been shown directly that feeding-induced obesity in mice causes an increase in tissue concentration of 4-HNE [14]. In turn, elevated 4-HNE realigns metabolism to favor fat deposition by increasing malonyl-CoA production, as described by us in the present report. We propose that these two partial processes – fat-induced 4-HNE generation and 4-HNE-triggered fat accumulation – form a positive feedback loop that perpetuates lipid storage as long as food is available. The proposed self-reinforcing loop is schematically depicted in Figure 8.

Although self-sustaining while food is available, the postulated regulatory circuit involving 4-HNE is not irreversible. When food becomes scarce (i.e., under caloric restriction conditions), metabolic and sensory inputs would act to shift metabolism to a mode that emphasizes somatic maintenance and utilization rather than storage of fat [55-57]. In this physiologic state, ROS generation is decreased, perhaps because of altered mitochondrial function [58]. Less ROS translates into

---

**Figure 7. Effect of increased 4-HNE levels on citrate concentration.** C. elegans were either treated with 1 mM 4-HNE according to the protocol described in the legend of Figure 5 (panel A) or subjected to RNAi to gst 10 (panel B). The results are shown as means ± S.D. of 3 to 6 independently grown worm populations.

**Figure 8. Proposed role of 4-HNE in the generation and maintenance of fat stores.**
less 4-HNE production. At the same time, decreased insulin-like signaling would augment the Daf-16-dependent expression of thegst-10 gene that encodes a 4-HNE-conjugating enzyme [21, 22]. The combination of limited supply and enhanced removal would lower the concentration of 4-HNE, thus decreasing the production of malonyl-CoA by reversing the mechanisms summarized in Figure 8. This would, in turn, limit fatty acid synthesis and permit fatty acid β-oxidation, as required for the utilization of fat as a metabolic fuel.

The mechanism proposed in Figure 8 suggests that the metabolic “pro-adipose bias” observed in the well-fed state can be reversed not only by withdrawal of food, but also by withdrawal of 4-HNE, even in the continuing presence of excess food. Pharmacological agents that act as 4-HNE scavengers have been reported [59-64]. Clearly, the 4-HNE-mediated mechanism we propose is not the only process that favors fat accumulation. Nevertheless, the potential importance of modulating 4-HNE levels in preventing or treating obesity could be considerable.

Modulation ofgst-10expression has opposite effects on fat accumulation and on life span ofC. elegans. Worms with silencedgst-10(andeducated 4-HNE) accumulate fat (Figure 2) and have a shortened life span [21], whereas overexpression ofgst-10results in a lean phenotype (Figure 2) and it prolongs life [22]. In mammals, on an epidemiological level obesity correlates with an increased risk for metabolic syndrome and earlier mortality [reviewed in ref. 65]; it has been recently suggested that oxidative stress-triggered fat deposition not only correlates with, but causes aging [66]. However, the link between fat accumulation, disease, and longevity, while undeniable, is complex and defies simple generalizations. The tissue distribution of lipid is an important factor. Recent data indicate that the primary trigger of metabolic syndrome in mammals is not total but ectopic fat, and that fat in adipose tissue may play a lesser role or could actually be protective by preventing the accretion of ectopic fat [65, 67-71]. Another factor that is relevant to longevity is the chemical nature of lipids, in particular the degree of unsaturation of fatty acids and the position of double bonds; highly peroxidizable polyunsaturated fatty acids may limit life span [72-77]. InC. elegans, fat accumulation has been found to be associated with either shortened or extended life span [48, 78-82], probably reflecting differences in fat localization, structure, or timing of fat abundance in the course of development. Recent work has demonstrated that lipid stores provide a metabolic link in the signaling pathway from germline stem cells to longevity, as well as in the mechanism by which lower Daf-2 activity leads to an extension of life [83]. In the latter work, the decreased fat stores that were associated with a longer life span were caused by induction of a triglyceride lipase. We report the same inverse relationship between fat and longevity when lipid stores are modulated by altering the supply of fatty acids [this work and refs. 20-22]. Therefore, our data support the notion that accumulation of fat, whether through increased synthesis or lowered utilization, can shorten life span ofC. elegans.

In summary, we have identified a biochemical mechanism, mediated through the lipid peroxidation product 4-HNE, that promotes fat accumulation. The mechanism is part of a positive feedback loop that confers a pro-adipose bias on organismal lipid homeostasis. The proposed mechanism differs from the better-known endocrine regulation of fat-related physiology by its purely biochemical nature. Therefore, the mechanism may offer heretofore unexplored opportunities for intervention.

**MATERIALS AND METHODS**

**C. elegans culture conditions.** *C. elegans* Bristol-N2 were cultured at 20°C on 2% agar plates containing nematode growth medium (NG medium: 25 mM potassium phosphate, pH 6.0, 50 mM NaCl, 0.6% (w/v) peptone, 5 μg/ml of cholesterol, 1 mM MgSO4, 1 mM CaCl2) and seeded with *Escherichia coli* strain OP50 [modified from ref. 84]. *E. coli* OP50 were grown in LB medium (10 g/l of Bacto-Tryptone, 5 g/l of Yeast Extract, 10 g/l of NaCl, pH 7.0).

The generation and maintenance of transgenic *C. elegans* overexpressinggst-10was described previously [22]. In experiments employing RNAi, *C. elegans* Bristol-N2 worms were fed *E. coli* strain HT115(DE3) transformed with an insert-free L4440 feeding vector (control), or the same vector carrying the appropriate insert. Specifically, RNAi againstgst-10was conducted according to [21]. RNAi againstalh-1andalh-10 was carried out using clones III-2N01 and X-3B18, respectively, from the RNAi library [85, 86] purchased from Geneservice Ltd, Cambridge, U.K. To induce the expression of double-stranded RNA, bacteria were treated with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG).

For liquid culture, synchronized *C. elegans* at the L4 stage (2.5 days post-hatch) were rinsed off plates and approximately 1,500 worms were placed in 3 ml S-buffer [0.1 M NaCl, 0.05 M potassium phosphate, pH 6.0; ref. 84] supplemented with cholesterol (3 μl of a 5 mg/ml stock solution in ethanol) and with the same E.
coli strain that was used for the initial growth on plates at a final density of $A_{600} = 1.0$. The cultures were maintained at 20°C except for *gst-10* overexpressors which were grown at 25°C. The medium was replaced every 12 hours with fresh medium containing the components listed above, including fresh bacteria.

Treatment of *C. elegans* with 4-HNE. Worms were maintained in liquid culture for 3 days under the conditions described above, except that 4-HNE (at concentrations ranging from zero to 2.0 mM) was added to the growth medium. Therefore, worms were exposed to fresh 4-HNE every 12 hours for a total of three days.

Nile red and Sudan black staining of *C. elegans*. For Nile red staining, worms were grown in liquid culture in medium supplemented with 75 ng/ml Nile Red (added as a 0.5 mg/ml stock solution in acetone). After 3 days of treatment with Nile red and, where used, with concurrently added 4-HNE, worms were washed for $3 \times 10$ min with S-buffer, and were placed on a slide and covered with a coverslip. Randomly selected fields were photographed under a fluorescence microscope (Nikon Eclipse E1000 equipped with a digital camera) using a 4× objective and an identical exposure time (300 ms) for all images. The filter cube consisted of a 465-495 nm excitation filter, a 505 nm long pass dichroic mirror, and a 540 nm long pass emission filter. Fluorescence spectra of Nile red-stained lipids of different polarity [23, 24, 87] indicate that this filter combination registers both neutral and polar lipids, although excitation for polar lipids is suboptimal. Therefore, under the conditions used, mostly neutral fat is quantitated.

For Sudan black B staining [88], worms were synchronized and processed as described in the preceding paragraph, except that Nile red was omitted from the solutions. After three days in liquid culture, worms were washed in S-buffer for 30 min, fixed with 1% paraformaldehyde in S buffer, and subjected to three freeze-thaw cycles. The animals were then dehydrated through consecutive washes with 25%, 50%, and 70% ethanol. Staining was performed overnight (approximately 16 hours) in a 50% saturated solution of Sudan black B in 70% ethanol. Following staining, worms were washed for $4 \times 10$ min with M9 buffer [6 g Na$_2$HPO$_4$, 3 g KH$_2$PO$_4$, 5 g NaCl and 0.25 g MgSO$_4$·7H$_2$O per liter; ref. 84] and randomly chosen fields were photographed under a brightfield microscope (Nikon Eclipse E1000 equipped with a digital camera) with Nomarski optics and a 4× objective. The exposure time (10 ms) was identical for all images.

ENZYME ASSAYS. Conjugation of 4-HNE with glutathione (GST activity) was measured according to Alin et al. [89] in whole-body homogenates of *C. elegans* obtained as described previously [20]. For the determination of NAD$^+$-dependent oxidation of 4-HNE (aldehyde dehydrogenase activity), worms from four 100-mm plates (approximately 10,000 animals) were washed with 50 mM Tris-HCl, pH 7.4, 5 mM EDTA, and stored at -70°C. Immediately before use, 0.1 ml of the above buffer were added to the worm pellet, and the suspension was sonicated on ice for $3 \times 10$ s and centrifuged for 20 min at 12,000 g at 4°C. Aldehyde dehydrogenase activity was assayed in the supernatant according to [90], except that 1 mM 4-HNE was used as the substrate instead of benzaldehyde, and 1 mM NAD$^+$ was used as the co-substrate instead of NADP$^+$.

**Determination of metabolite levels.** For the determination of citrate, frozen worms were homogenized in 1 M perchloric acid. Following centrifugation, the supernatant was neutralized and citrate was measured by a coupled enzyme assay utilizing citrate lyase and malate and lactate dehydrogenases [91], as implemented in the citric acid determination kit by Boehringer Mannheim/ R-Biopharm (Roche, Marshall, MI).

To assay malonyl-CoA, worm pellets were frozen and stored at -70°C. On the day of assay, the pellets were pulverized in a mortar at liquid nitrogen temperature, and were lyophilized overnight. The weight of the powder was recorded, and the samples were processed and malonyl-CoA was determined by HPLC by a modification of the method of Lazzarino et al. [92] as described by us previously [19].
Assay of 4-HNE-protein adducts. The level of 4-HNE-modified proteins was determined by competitive ELISA [93] as modified by us previously [20].

Materials. 4-HNE dimethylacetal was synthesized according to [94, 95]. 4-HNE was prepared on the day of use by hydrolysis of 4-HNE dimethylacetal in 1 mM HCl for 1 hour at room temperature. Sudan black B was from Aldrich (Milwaukee, WI; catalog number 19,966-4), and Nile red was from Molecular Probes (Carlsbad, CA; catalog number N-1142).

CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

This work was supported in part by National Institutes of Health grants R01 AG028088 and AG018845 (to P.Z.). P.Z. is a recipient of a VA Research Career Scientist Award.

REFERENCES

1. Guichardant M, Bacot S, Moliere P, Lagarde M. Hydroxyalkenals from the peroxidation of n-3 and n-6 fatty acids and urinary metabolites. Prostaglandins Leukot Essent Fatty Acids 2006; 75: 179-182.
2. Long EK, Murphy TC, Leiphon LJ, Watt J, Morrow JD, Milne GL, Howard JR, Picklo MJ, Sr. Trans-4-hydroxy-2-hexenal is a neurotoxic product of docosahexaenoic (22:6; n-3) acid oxidation. J Neurochem. 2008; 105: 714-724.
3. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991; 11: 81-128.
4. Grimsrud PA, Xie H, Griffen TJ, Bernlohr DA. Oxidative stress and covalent modification of protein with bioactive aldehydes. J Biol Chem. 2008; 283: 21837-21841.
5. Poli G, Schaur RJ, Siems WG, Leonardiuzzi G. 4-Hydroxynonenal: a membrane lipid oxidation product of medicinal interest. Med Res Rev. 2008; 28: 569-631.
6. Petersen DR, Doorn JA. Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med. 2004; 37: 937-945.
7. Leonardiuzzi G, Robbesyn F, Poli G. Signaling kinases modulated by 4-hydroxynonenal. Free Radic Biol Med. 2004; 37: 1694-1702.
8. Dwivedi S, Sharma A, Patrick B, Sharma R, Awasthi YC. Role of 4-hydroxynonenal and its metabolites in signaling. Redox Rep. 2007; 12: 4-10.
9. Forman HJ, Fukuto JM, Miller T, Zhang H, Rinna A, Levy S. The chemistry of cell signaling by reactive oxygen and nitrogen species and 4-hydroxynonenal. Arch Biochem Biophys. 2008; 477: 183-195.
10. Rajala MW, Scherer PE. The adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003; 144: 3765-3773.
11. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Falolia E, Wang SL, Greenberg AS, Obin MS. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005; 46: 2347-2355.
12. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circulation Res. 2005; 96: 939-949.
13. Russell AP, Gastaldi G, Bobbioni-Harsch E, Arboit P, Gobelet C, Deriaz O, Golay A, Witztum JL, Giacobino J-P. Lipid peroxidation in skeletal muscle of obese as compared to endurance-trained humans: a case of good vs. bad lipids? FEBS Lett. 2003; 551: 104-106.
14. Grimsrud PA, Picklo Sr MJ, Griffin TJ, Bernlohr DA. Carboxylation of adipose proteins in obesity and insulin resistance: Identification of adipocyte fatty acid-binding protein as a cellular target of 4-hydroxynonenal. Mol Cell Proteomics 2007; 6: 624-637.
15. Awasthi YC, Sharma R, Sharma A, Yadav S, Singhal SS, Chaudary P, Awasthi S. Self-regulatory role of 4-hydroxynonenal in signaling for stress-induced programmed cell death. Free Radic Biol Med. 2008; 45: 111-118.
16. Kutuk O, Basaga H. Apoptosis signalling by 4-hydroxynonenal: a role for JNK-c-Jun/AP-1 pathway. Redox Rep. 2007; 12: 30-34.
17. Echtay KS, Brand MD. 4-hydroxy-2-nonenal and uncoupling proteins: an approach for regulation of mitochondrial ROS production. Redox Rep. 2007; 12: 26-29.
18. Barra G, Pizzimenti S, Dianzani MU. Lipid peroxidation: control of cell proliferation, cell differentiation and cell death. Mol Aspects Med. 2008; 29: 1-8.
19. Singh SP, Niemczyk M, Saini D, Awasthi YC, Zimniak L, Zimniak P. Role of the electrophilic lipid peroxidation product 4-hydroxynonenal in the development and maintenance of obesity in mice. Biochemistry 2008; 47: 3900-3911.
20. Ayyadevara S, Dandapat A, Singh SP, Siegel ER, Shmoookler Reis RJ, Zimniak L, Zimniak P. Life span and stress resistance of Caenorhabditis elegans are differentially affected by glutathione transferases metabolizing 4-hydroxynon-2-enal. Mech Ageing Dev. 2007; 128: 196-205.
21. Ayyadevara S, Dandapat A, Singh SP, Beneš H, Zimniak L, Shmoookler Reis RJ, Zimniak P. Lifespan extension in hypomorphic daf-2 mutants of Caenorhabditis elegans is partially mediated by glutathione transferase CegSTP2-2. Aging Cell 2005; 4: 299-307.
22. Ayyadevara S, Engle MR, Singh SP, Dandapat A, Lichti CF, Beneš H, Shmoookler Reis RJ, Liebau E, Zimniak P. Lifespan and stress resistance of Caenorhabditis elegans are increased by expression of glutathione transferases capable of metabolizing the lipid peroxidation product 4-hydroxynonenal. Aging Cell 2005; 4: 257-271.
23. Greenspan P, Fowler SD. Spectrofluorometric studies of the lipid probe, nile red. J Lipid Res. 1985; 26: 781-789.
24. Greenspan P, Mayer EP, Fowler SD. Nile red: a selective fluorescent stain for intracellular lipid droplets. J Cell Biol. 1985; 100: 965-973.
25. McKay RM, McKay JP, Avery L, Graff JM. C. elegans: a model for exploring the genetics of fat storage. Dev Cell 2003; 4: 131-142.
26. Marchitti SA, Orlicky DJ, Vasiiliou V. Expression and initial characterization of human ALDH3B1. Biochem Biophys Res Commun. 2007; 356: 792-798.

27. Townsend AJ, Leone-Kabler S, Haynes RL, Wu Y, Szwed L, Bunting KD. Selective protection by stably transfected human ALDH3A1 (but not human ALDH1A1) against toxicity of aliphatic aldehydes in V79 cells. Chem Biol Interact. 2001; 130-132: 261-273.

28. Singh SP, Chen T, Chen L, Mei N, McLain E, Samokyszyn V, Thaden JJ, Moore MM, Zimmik P. Mutagenic effects of 4-hydroxynonenal triacetate, a chemically protected form of the lipid peroxidation product 4-hydroxynonenal, as assayed in LS178Y/Tk⁻ mouse lymphoma cells. J Pharmacol Exp Ther. 2005; 313: 855-861.

29. Schutt F, Bergmann M, Holz FG, Kopitz J. Proteins modified by malondialdehyde, 4-hydroxynonenal, or advanced glycation end products in lipofuscin of human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2003; 44: 3663-3668.

30. Zimmik P, Singhal SS, Srivastava SK, Awasthi S, Sharma R, Hayden JB, Awasthi YC. Estimation of genomic complexity, heterologous expression, and enzymatic characterization of mouse glutathione S-transferase mGSTA4-4 (GST 5.7). J Biol Chem. 1994; 269: 992-1000.

31. Wonisch W, Zellng G, Kohlwein SD, Schaur RJ, Bilinski T, Tatzer B, Esterbauer H. Ultrastructural analysis of HNE-treated Saccharomyces cerevisiae cells reveals fragmentation of the vacuole and an accumulation of lipids in the cytosol. Cell Biochem Funct. 2001; 19: 59-64.

32. Lefrancois-Martinez A-M, Tournare C, Martinez A, Berger M, Daudal S, Tritsch D, Veyssiere G, Jean C. Product of side-chain cleavage of cholesterol, isocapraldehyde, is an endogenous specific substrate of mouse vas deferens protein, an aldose reductase-like protein in adenocortical cells. J Biol Chem. 1999; 274: 32875-32880.

33. Tirard J, Gout J, Lefrancois-Martinez AM, Martinez A, Begeot M, Naville D. A novel inhibitory protein in adipose tissue: the aldo-keto-reductase AKR1B7. Its role in adipogenesis. Endocrinology 2007; 148: 1996-2005.

34. Zimmik P, Singh SP (2006). Families of glutathione transferases. In Toxicology of glutathione transferases, Y.C. Awasthi, ed. (Boca Raton, FL: CRC Press), pp. 11-26.

35. Brenner S. The genetics of behaviour. Br Med Bull. 1973; 29: 269-271.

36. Saggerson D. Malonyl-CoA, a key signaling molecule in mammalian cells. Annu Rev Nutr. 2008; 28: 253-272.

37. Abu-Elheiga L, Matzuk MM, Abo-Hashema KA, Wakil SJ. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 2001; 291: 2613-2616.

38. Boucher A, Lu D, Burgess SC, Telemaque-Potts S, Jensen MV, Mulder H, Wang MY, Unger RH, Sherry AD, Newgard CB. Biochemical mechanism of lipid-induced impairment of glucose-stimulated insulin secretion and reversal with a malate analogue. J Biol Chem. 2004; 279: 27263-27271.

39. Harwood HJ, Jr. Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. Expert Opin Ther Targets 2005; 9: 267-281.

40. Ashkafi K, Chang FY, Watts JL, Fraser AG, Kamath RS, Ahringer J, Ruvkun G. Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature 2004; 421: 268-272.

41. Andreelli F, Foretz M, Knauf C, Cani PD, Perrin C, Iglesias MA, Pilott B, Bado A, Tronche F, Milteux G, Vaulont S, Burcelin R, Viollet B. Liver adenosine monophosphate-activated kinase-α2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 2006; 147: 2432-2441.

42. Viollet B, Moumier R, Leclerc J, Yazigi A, Foretz M, Andreelli F. Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metabol. 2007; 33: 395-402.

43. Reszko AE, Kasumov T, David F, Thomas KR, Jobbins KA, Cheng JF, Lopaschuk GD, Dyck JR, Diaz M, Des Rosiers C, Stanley WC, Brunengraber H. Regulation of malonyl-CoA concentration and turnover in the normal heart. J Biol Chem. 2004; 279: 34298-34301.

44. Curtis R, Geesaman BJ, DiStefano PS. Ageing and metabolism: drug discovery opportunities. Nat Rev Drug Discov. 2005; 4: 569-580.

45. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002; 415: 339-343.

46. Takekoshi K, Fukushima M, Quin Z, Nissato S, Isobe K, Kawakami Y, Ohmori H. Long-term exercise stimulates adenosine monophosphate-activated protein kinase activity and subunit expression in rat visceral adipose tissue and liver. Metabolism 2006; 55: 1122-1128.

47. Barber MC, Price NT, Travers MT. Structure and regulation of acetyl-CoA carboxylase genes of methanoa. Biochim Biophys Acta 2005; 173: 1-28.

48. Schulz TJ, Zarse K, Voigt A, Urban N, Birringer M, Ristow M. Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell Metabol. 2007; 6: 280-293.

49. Munday MR. Regulation of mammalian acetyl-CoA carboxylase. Biochem Soc Trans. 2002; 30: 1059-1064.

50. Hassel B, Sonnewald U, Ursung G, Fonnum F. NMR spectroscopy of cultured astrocytes: effects of glutamate and the gilothoxin fluorocitrato. J Neurochem. 1994; 62: 2187-2194.

51. Stevens SM, Jr., Rauniar N, Prokai L. Rapid characterization of covalent modifications to rat brain mitochondrial proteins after ex vivo exposure to 4-hydroxy-2-nonenal by liquid chromatography-tandem mass spectrometry using data-dependent and neutral loss-driven MS³ acquisition. J Mass Spectrom. 2007; 42: 1599-1605.

52. Raza H, John A, Brown EM, Benedict S, Kambal A. Alterations in mitochondrial respiratory functions, redox metabolism and apoptosis by oxidant 4-hydroxynonenal and antioxidants curcumin and melatonin in PC12 cells. Toxicol Appl Pharmacol. 2007; 226: 161-168.

53. Festa A, D’Agostino R, Jr., Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord. 2001; 25: 1407-1415.

54. Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG, Keaney JF, Jr., Meigs JB, Lipinska I, Katheresan S, Murabito JM, O’Donnell C J, Benjamin EJ, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress. The Framingham Heart Study. Circulation 2007; 116: 1234-1241.
55. Kirkwood TB. Understanding the odd science of aging. Cell 2005; 120: 437-447.
56. Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature 2006; 444: 868-874.
57. Libert S, Zwiener J, Chu X, Vanvoorhies W, Roman G, Pletcher SD. Regulation of Drosophila life span by olfaction and food-derived odors. Science 2007; 315: 1133-1137.
58. Guarente L. Mitochondria - a nexus for aging, calorie restriction, and sirtuins? Cell 2008; 132: 171-176.
59. Burcham PC, Kaminskas LM, Fontaine FR, Petersen DR, Pyke SM. Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products. Toxicology 2002; 181-182: 229-236.
60. Guarente L, Mattson MP, Borin G. Synthesis and evaluation of neuroprotective \( \alpha,\beta \)-unsaturated aldehyde scavenger histidyl-containing analogues of carnosine. J Medicinal Chem. 2005; 48: 6156-6161.
61. Burcham PC, Pyke SM. Hydralazine inhibits rapid acrolein-induced protein oligomerization: role of aldehyde scavenging and adduct trapping in cross-link blocking and cytoprotection. Mol Pharmacol. 2006; 69: 1056-1065.
62. Tang SC, Arumugam TV, Cutler RG, Jo DG, Magnus T, Chan SL, Mughal MR, Telljohann RS, Nassar M, Ouyang X, Calderon A, Ruzza P, Guiotto A, et al. Neuroprotective actions of a histidine analogue in models of ischemic stroke. J Neurochem. 2007; 101: 729-736.
63. Aldini G, Dalle-Donne I, Colombo R, Maffei Facino R, Miliziani A, Carini M. Lipoxidation-derived reactive carbonyl species as potential drug targets in preventing protein carbonylation and related cellular dysfunction. ChemMedChem 2006; 1: 1045-1058.
64. Galvani S, Coatricieux C, Elbaz M, Grazide MH, Jean Claude T, Parini A, Uchida K, Kamar N, Rostaing L, Baltas M, Salvayre R, Negre-Salvayre A. Carboxyl scavenger and antiatherogenic effects of hydrazine derivatives. Free Radic Biol Med. 2008; 45: 1457-1467.
65. Virtue S, Vidal-Puig A. It’s not how fat you are, it’s what you do with it that counts. PLoS Biol. 2008; 6: e237.
66. Berniakovich I, Trinei M, Stendardo M, Migliaccio E, Minucci S, Bernardi P, Pellici PG, Giorgio M. p66\( \gamma \)-generated oxidative signal promotes fat accumulation. J Biol Chem. 2008; 283: 34283-34293.
67. De Gregorio GB, Yao-Borengasser A, Rasouli N, Varma V, Lu T, Miles LM, Ranganathan G, Peterson CA, McGehee RE, Kern PA. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005; 54: 2305-2313.
68. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006; 55: 1537-1545.
69. Rasouli N, Molavi B, Elbein SC, Kern PA. Ectopic fat accumulation and metabolic syndrome. Diabetes Obes Metab. 2007; 9: 1-10.
70. Wang MY, Grayburn P, Chen S, Ravazolla M, Orci L, Unger RH. Adipogenic capacity and the susceptibility to type 2 diabetes and metabolic syndrome. Proc Natl Acad Sci USA 2008; 105: 6139-6144.
71. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, Schraw T, Durand JL, Li H, Li G, Jelicks LA, Mehler MF, Hui DY, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest. 2007; 117: 2621-2637.
72. Hulbert AJ. On the importance of fatty acid composition of membranes for aging. J Theor Biol. 2005; 234: 277-288.
73. Barja G. Free radicals and aging. Trends Neurosci. 2004; 27: 595-600.
74. Pamplona R, Barja G, Portero-Otin M. Membrane fatty acid unsaturation, protection against oxidative stress, and maximum life span: a homeoviscous-longevity adaptation? Ann NY Acad Sci. 2002; 959: 475-490.
75. Sanz A, Pamplona R, Barja G. Is the mitochondrial free radical theory of aging intact? Antioxid Redox Signal. 2006; 8: 582-599.
76. Hulbert AJ, Faulks SC, Harper JM, Miller RA, Buffenstein R. Extended longevity of wild-derived mice is associated with peroxidation-resistant membranes. Mech Ageing Dev. 2006; 127: 653-657.
77. Hulbert AJ, Pamplona R, Buffenstein R, Buttemer WA. Life and death: metabolic rate, membrane composition, and life span of animals. Physiol Rev. 2007; 87: 1175-1213.
78. Mukhopadhyay A, Deplancke B, Walhout AJM, Tissinbaum HA. C. elegans tubby regulates life span and fat storage by two independent mechanisms. Cell Metabol. 2005; 2: 35-42.
79. Riddle DL (1988). The dauer larva. In The nematode C elegans. W.B. Wood, ed. (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press), pp. 393-412.
80. Garigan D, Hsu AL, Fraser AG, Kamath RS, Ahringer J, Kenyon C. Genetic analysis of tissue aging in Caenorhabditis elegans: A role for heat-shock factor and bacterial proliferation. Genetics 2002; 161: 1101-1112.
81. Fei YJ, Liu JC, Inoue K, Zhuang L, Miyake K, Miyauchi S, Ganapathy V. Relevance of NAC-2, an Na\(^{+}\)-coupled citrate transporter, to life span, body size and fat content in Caenorhabditis elegans. Biochem J. 2004; 379: 191-198.
82. Szewczyk NJ, Udranszky IA, Kozak E, Sunga J, Kim SK, Jacobson LA, Conley CA. Delayed development and lifespan extension as features of metabolic lifestyle alteration in C. elegans under dietary restriction. J Exp Biol. 2006; 209: 4129-4139.
83. Wang MC, O'Rourke EJ, Ruvkun G. Fat metabolism links germline stem cells and longevity in C. elegans. Science 2008; 322: 957-960.
84. Brenner S. The genetics of Caenorhabditis elegans. Genetics 1974; 77: 71-94.
85. Kamath RS, Fraser AG, Dong Y, Poulin G, Dubrin R, Gotta M, Kanapin A, Le Bot N, Moreno S, Sohrmann M, Welchman DP, Zipperlen P, Ahringer J. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 2003; 421: 231-237.
86. Kamath RS, Ahringer J. Genome-wide RNAi screening in Caenorhabditis elegans. Methods 2003; 30: 313-321.
87. Talreja P, Kleene NK, Pickens WL, Wang TF, Kasting GB. Visualization of the lipid barrier and measurement of lipid pathlength in human stratum corneum. AAPS PharmSci. 2001; 3: E13.
88. Ogg S, Ruvkun G. The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. Mol Cell 1998; 2: 887-893.
89. Alin P, Danielson UB, Mannervik B. 4-Hydroxyalk-2-enals are substrates for glutathione transferase. FEBS Lett. 1985; 179: 267-270.
90. Bunting KD, Lindahl R, Townsend AJ. Oxazaphosphorine-specific resistance in human MCF-7 breast carcinoma cell lines expressing transfected rat class 3 aldehyde dehydrogenase. J Biol Chem. 1994; 269: 23197-23203.

91. Möllering H, Gruber W. Determination of citrate with citrate lyase. Anal Biochem. 1966; 17: 369-376.

92. Lazzarino G, Amorini AM, Fazzina G, Vagnozzi R, Signoretti S, Donzelli S, Di Stasio E, Giardina B, Tavazzi B. Single-sample preparation for simultaneous cellular redox and energy state determination. Anal Biochem. 2003; 322: 51-59.

93. Satoh K, Yamada S, Koike Y, Igarashi Y, Toyokuni S, Kumano T, Takahata T, Hayakari M, Tsuchida S, Uchida K. A 1-hour enzyme-linked immunosorbent assay for quantitation of acrolein- and hydroxynonenal-modified proteins by epitope-bound casein matrix method. Anal Biochem. 1999; 270: 323-328.

94. Gree R, Tourbah H, Carrie R. Fumaraldehyde monodimethyl acetal: an easily accessible and versatile intermediate. Tetrahedron Lett. 1986; 27: 4983-4986.

95. Chandra A, Srivastava SK. A synthesis of 4-hydroxy-2-trans-nonenal and 4-[3H] 4-hydroxy-2-trans-nonenal. Lipids 1997; 32: 779-782.